NCT00482378View on ClinicalTrials.gov

Samarium Sm 153 Lexidronam Pentasodium Combined With Zoledronic Acid or Pamidronate in Treating Patients With Relapsed or Refractory Multiple Myeloma and Bone Pain

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

March 21, 2005

Primary Completion Date

May 22, 2007

Study Completion Date

December 2, 2008

Conditions
Multiple Myeloma and Plasma Cell NeoplasmPain
Interventions
DRUG

Pamidronate

90 mg by IV monthly.

DRUG

Zoledronic acid

4 mg by IV monthly.

RADIATION

Sm 153 lexidronam

0.5 mCi/kg or 1 mCi/kg by IV.

Trial Locations (1)

55905

Mayo Clinic, Rochester

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Mayo Clinic

OTHER